Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML
Recruiting
Phase 1
Phase 2
Interventional Study
Acute Myeloid Leukemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 6 Months – 30
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 15 (estimated)
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells for children/young adults with primary high risk or refractory AML and relapsed AML.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Patients:
* primary high risk AML
* primary refractory AML
* relapsed AML
* Karnofsky or Lansky performance scale greater or equal to 70
* written informed consent
Donors:
* haploidentical family donor
* donor suitable for cell donation and apheresis according to standard cri…
Contacts